KRAS and carcinoma: Mutations in KRAS were prevalent in mixed (1/3, 33.3%) and endometrioid (1/5, 20.0%) carcinomas, less frequent in serous samples (4/64, 6.2%), and an exclusive event in the clear cell tumor sample (1/1, 100.0%) (Figure 2a–c,g).